A multicentre, multinational, randomised, double blind, single dummy, parallel group, placebo-controlled trial to investigate the dose-response and safety of Fentanyl TAIFUN 100 µg, 200 µg, 400 µg in the treatment of breakthrough pain in patients with cancer on maintenance opioid therapy for persistent pain.

Trial Profile

A multicentre, multinational, randomised, double blind, single dummy, parallel group, placebo-controlled trial to investigate the dose-response and safety of Fentanyl TAIFUN 100 µg, 200 µg, 400 µg in the treatment of breakthrough pain in patients with cancer on maintenance opioid therapy for persistent pain.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2011

At a glance

  • Drugs Fentanyl; Fentanyl
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Acronyms FIND
  • Most Recent Events

    • 22 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top